Skip to main content

Advertisement

SpringerLink
Log in

Phase II trial to topotecan in hepatocellular carcinoma: A Southwest Oncology Group study

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

Hepatocellular carcinoma remains a highly chemoresistant neoplasm. In this study of the topoisomerase I inhibitor topotecan a response rate of 13.9% (95% confidence interval 4.7%–29.5%) was obtained utilizing a five consecutive day bolus infusion schedule. There were no complete responses and the median survival was only eight months. Furthermore, treatment with topotecan produced significant toxicity with two-thirds of patients experiencing life-threatening (grade 4) neutropenia. When used in this dose and schedule, topotecan does not appear to be effective for patients with advanced hepatocellular carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lotze MT, Flickinger JC, Carr BI: Hepatobiliary Neoplasms. In: Devita V, Hellman S, Rosenberg S (eds) Cancer: Principles and Practice of Oncology, 4th ed. JB Lippincott Co., Philadelphia, 1993, pp 883–914.

    Google Scholar 

  2. Luporini G, Labianca R, Pancera G: Medical treatment of hepatocellular carcinoma. J Surg Oncol Suppl 3: 115–118, 1993.

    Google Scholar 

  3. Creemers GJ, Lund B, Verweij J: Topoisomerase I inhibitors: topotecan and irenotecan. Cancer Treat Rev 20: 73–96, 1994.

    Google Scholar 

  4. Johnson RK, McCabe FL, Faucette LF, Hertzberg RP, Kingsbury WD, Boehm JC, Caranfa MJ, Holden KG: SK&F 104864, a water-soluble analog of camptothecin with broad-spectrum activity in preclinical tumor models. (Abstract) Proc Amm Assoc Cancer Res 30: 623, 1989.

    Google Scholar 

  5. Wall J, Burris H, Von Hoff D, Rodriguez G, Kneuper-Hall R, Shaffer D, O'Rourke T, Brown T, Weiss G, Clark G, McVea S, Brown J, Johnson R: A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days. Anti-Cancer Drugs 3: 337–345, 1992.

    Google Scholar 

  6. Rowinsky E, Grochow L, Hendricks C, Ettinger D, Forastiere A, Hurowitz L, McGuire W, Sartorius S, Lubejko S, Kaufmann S, Donchower R: Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor. J Clin Oncol 10: 647–656, 1992.

    Google Scholar 

  7. Sirott M, Saltz L, Young C, Tong W, Trochanowski B, Niedzwiecki D, Toomasi F, Kelsen D: Phase I and clinical pharmacologic study of intravenous topotecan (T). (Abstract) Proc Am Soc Clin Oncol 10: 104, 1991.

    Google Scholar 

  8. Recondo G, Abbruzzese J, Newman B, Newman R, Kuhn J, Von Hoff D, Garteiz D, Raber M: A phase I trial of topotecan (TOPO) administered by a 24-hour infusion. (Abstract) Proc Amer Assoc Cancer Res 32: 206, 1991.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cabarrus Memorial Hospital, Concord, NC

    James G. Wall

  2. Southwest Oncology Group Statistical Center, Seattle, WA

    Jacqueline K. Benedetti

  3. Ohio State University Health Center, Columbus, OH

    Mark A. O'Rourke

  4. University of Southern California School of Medicine, Los Angeles, CA

    Ronald B. Natale

  5. Temple University, Philadelphia, PA, USA

    John S. Macdonald

Authors
  1. James G. Wall
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jacqueline K. Benedetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mark A. O'Rourke
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ronald B. Natale
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. John S. Macdonald
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wall, J.G., Benedetti, J.K., O'Rourke, M.A. et al. Phase II trial to topotecan in hepatocellular carcinoma: A Southwest Oncology Group study. Invest New Drugs 15, 257–260 (1997). https://doi.org/10.1023/A:1005851804533

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1005851804533

Search

Navigation